Mid-cap Health Care company Lantheus has logged a -0.4% change today on a trading volume of 60,525. The average volume for the stock is 1,088,962.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. Based in Bedford, United States the company has 698 full time employees and a market cap of $4,524,295,680.
The company is now trading -45.58% away from its average analyst target price of $121.5 per share. The 8 analysts following the stock have set target prices ranging from $110.0 to $130.0, and on average give Lantheus a rating of buy.
Over the last 12 months LNTH shares have declined by -24.0%, which represents a difference of -31.0% when compared to the S&P 500. The stock's 52 week high is $100.85 per share and its 52 week low is $47.46. With its net margins declining an average -34.2% over the last 6 years, Lantheus declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-23 | 935,061 | 28,067 | 3 | 117.65 |
| 2022-02-24 | 425,208 | -71,279 | -17 | -325.0 |
| 2021-02-25 | 339,410 | -13,473 | -4 | -144.44 |
| 2020-02-25 | 347,337 | 31,667 | 9 | -25.0 |
| 2019-02-20 | 343,374 | 40,518 | 12 | -67.57 |
| 2018-02-26 | 331,378 | 123,385 | 37 |
